摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-吡咯烷甲酸甲酯盐酸盐 | 198959-37-4

中文名称
3-吡咯烷甲酸甲酯盐酸盐
中文别名
甲基3-吡咯烷-甲酸甲酯盐酸盐;甲基-3-吡咯烷-甲酸甲酯盐酸盐;3-吡咯烷羧酸甲酯盐酸盐;甲基3- 吡咯烷-甲酸甲酯 盐酸盐;甲基3-吡咯烷-甲酸甲酯 盐酸盐;3-吡咯烷甲酸甲酯盐酸盐:
英文名称
methyl pyrrolidine-3-carboxylate hydrochloride
英文别名
methyl 3-pyrrolidinecarboxylate hydrochloride;pyrrolidine-3-carboxylic acid methyl ester hydrochloride;methyl pyrrolidine-3-carboxylate;hydrochloride
3-吡咯烷甲酸甲酯盐酸盐化学式
CAS
198959-37-4
化学式
C6H11NO2*ClH
mdl
MFCD08436169
分子量
165.62
InChiKey
VVBSXSVVMNGQIN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.26
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    38.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥环境中保存。

SDS

SDS:bda92a9570e9ca0f00f981085840196c
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 3-pyrrolidinecarboxylate HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-pyrrolidinecarboxylate HCl
CAS number: 198959-37-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H11NO2.ClH
Molecular weight: 165.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    3-吡咯烷甲酸甲酯盐酸盐potassium carbonatelithium hexamethyldisilazane 作用下, 以 四氢呋喃 为溶剂, 反应 2.33h, 生成 1-benzyl 3-methyl 3-methylpyrrolidine-1,3-dicarboxylate
    参考文献:
    名称:
    [EN] PYRROLOPYRIDINES AS KINASE INHIBITORS
    [FR] PYRROLOPYRIDINES EN TANT QU'INHIBITEURS DE KINASE
    摘要:
    公式(I)的化合物对于CHKl和/或CHK2的抑制是有用的。本文揭示了使用公式(I)的化合物及其立体异构体和药学上可接受的盐,以进行哺乳动物细胞中的体外、体内和原位诊断、预防或治疗这些疾病,或相关的病理条件的方法。
    公开号:
    WO2009140320A1
  • 作为产物:
    描述:
    1-Boc-吡咯烷-3-甲酸甲酯盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 4.0h, 生成 3-吡咯烷甲酸甲酯盐酸盐
    参考文献:
    名称:
    [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    [FR] COMPOSÉS PYRAZOLE SUBSTITUÉS À UTILISER EN TANT QU'INHIBITEURS DE SÉRINE PROTÉASE
    摘要:
    提供了一些多取代芳香族化合物,其中包括取代吡唑基,用于抑制凝血酶和/或激肽释放酶。此外,还提供了药物组合物。此外,还提供了一种治疗和预防某些疾病或疾病的方法,这些疾病或疾病可以通过抑制凝血酶和/或激肽释放酶进行治疗或预防。
    公开号:
    WO2016138532A1
点击查看最新优质反应信息

文献信息

  • [EN] RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRAZOLO- ET TRIAZOLO-PYRIMIDINE ANTIVIRAUX DU VIRUS RESPIRATOIRE SYNCYTIAL (VRS)
    申请人:JANSSEN SCIENCES IRELAND UC
    公开号:WO2016174079A1
    公开(公告)日:2016-11-03
    The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    这项发明涉及具有抗病毒活性的新型取代吡唑并三唑基嘧啶化合物,其化学式为(I),特别是对呼吸道合胞病毒(RSV)复制具有抑制活性。该发明还涉及包含这些化合物的药物组合物,以及用于治疗呼吸道合胞病毒感染的化合物。
  • DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES
    申请人:Kasai Shizuo
    公开号:US20120071489A1
    公开(公告)日:2012-03-22
    The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4.
    本发明涉及一种化合物,其化学式如下所示,其中每个符号如本说明书中所定义,该化合物具有优越的降低RBP4作用,并且可用作预防或治疗由RBP4增加介导的疾病或病况的药物组合物。
  • [EN] N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
    申请人:BIOMARIN PHARM INC
    公开号:WO2015065937A1
    公开(公告)日:2015-05-07
    Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    本处描述的是公式I的化合物,制造此类化合物的方法,包含此类化合物的药物组合物和药品,以及用于治疗或预防与葡萄糖苷鞘氨醇合酶(GCS)相关疾病的I化合物。
  • [EN] HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE<br/>[FR] PYRROLOPYRIDINES À SUBSTITUTION HÉTÉROCYCLYLE UTILISÉES EN TANT QU'INHIBITEURS DE LA KINASE CDK12
    申请人:UNIV NOTTINGHAM
    公开号:WO2019058132A1
    公开(公告)日:2019-03-28
    This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
    这项发明涉及抑制CDK12激酶的化合物。这些化合物可用于治疗由CDK12激酶介导的疾病,包括1型肌强直性营养不良(DM1)和其他由RNA重复扩展转录物引起的疾病。特别是,该发明涉及公式(I)的化合物,或其药用可接受的盐或N-氧化物,其中R1a, R2, R3, R4a, R4b和R4c按本文定义。
  • [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QUE MODULATEURS DU TNF ALPHA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2017023905A1
    公开(公告)日:2017-02-09
    Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is -(CR7R7)m-; L2 is -(CR7R7)n-; and X, Z, R1, R2, R3, R4, R5,and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    披露了公式(I)化合物或其盐,其中:A是CR1或N;B是CR3或N;D是CR4或N;L1是-(CR7R7)m-;L2是-(CR7R7)n-;X,Z,R1,R2,R3,R4,R5和R6都在此定义。还披露了将此类化合物用作调节TNFα的调节剂的方法,以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦